Lack of dose dependent kinetics of methyl salicylate-2-O-β-d-lactoside in rhesus monkeys after oral administration

He, Yangyang; Yu, Yan; Zhang, Tiantai; Ma, Yinglong; Zhang, Wen; Wu, Peng; Song, Junke; Wang, Shuang; Du, Guanhua

doi:10.1016/j.jep.2014.12.063

Cited by 1 publication

(1 citation statement)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 In preclinical pharmacokinetic experiments, MSL has been proved to have good absorption from the gastrointestinal tract in Canidae and primates, and its main metabolite, salicylic acid, presents good pharmacokinetic features after oral administration. 18 , 19 It remains to be elucidated whether the novel salicylic acid analogue is efficacious for the treatment of SLE. The aim of the present study was to investigate the potential therapeutic effect of MSL on SLE, and explore the underlying mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

He¹,

Yu²,

Zhang³

et al. 2016

DDDT

Self Cite

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE), with a high incidence rate and insufficient therapy worldwide, is a complex disease involving multiple organs characterized primarily by inflammation due to deposition of immunocomplexes formed by production of autoantibodies. The mechanism of SLE remains unclear, and the disease still cannot be cured. We used pristane to induce SLE in female BALB/c mice. Methyl salicylate 2-O-β-d-lactoside (MSL; 200, 400, and 800 mg/kg) was orally administered 45 days after pristane injection for 4.5 months. The results showed that MSL antagonized the increasing levels of multiple types of antibodies and cytokines in lupus mice. MSL was found to suppress joint swelling and have potent inhibitory effect on arthritis-like symptoms. MSL also significantly decreased the spleen index and expression of inflammatory markers in the lupus mice. MSL protected the kidneys of lupus mice from injury through inhibiting the expression of inflammatory cytokines and reducing the IgG and C3 immunocomplex deposits. Further Western blot assays revealed that the downregulation of the intracellular inflammatory signals of NFκB and JAK/STAT3 might be the potential molecular mechanisms of the pharmacological activity of MSL against SLE in vivo. These findings may demonstrate that MSL has the potential to be a useful and highly effective treatment for SLE.

show abstract

Section: Introductionmentioning

confidence: 99%

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

He¹,

Yu²,

Zhang³

et al. 2016

DDDT

Self Cite

View full text Add to dashboard Cite

show abstract

Lack of dose dependent kinetics of methyl salicylate-2-O-β-d-lactoside in rhesus monkeys after oral administration

Cited by 1 publication

References 13 publications

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

Contact Info

Product

Resources

About

Lack of dose dependent kinetics of methyl salicylate-2-O-β-d-lactoside in rhesus monkeys after oral administration

Cited by 1 publication

References 13 publications

Methyl salicylate 2-<em>O</em>-&beta;-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

Methyl salicylate 2-<em>O</em>-&beta;-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

Contact Info

Product

Resources

About

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction

Methyl salicylate 2-<em>O</em>-β-D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction